Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Process-oriented dynamic group psychotherapy for depression as a teaching modality in a family medicine residency program- A pilot study.

Simon EP, McClaflin R, Zonca R, Mikuni K, Chung W, Etnyre E, Faucette L, Oates D, Merrill C.

Int J Psychiatry Med. 2017 Jan;52(1):62-71. doi: 10.1177/0091217417703290. Epub 2017 Apr 6.

PMID:
28486880
2.

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.

Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr, Dhanak D, Bergnes G, Sakowicz R, Jackson JR.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44. doi: 10.1073/pnas.0915068107. Epub 2010 Feb 18.

3.

Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.

Oakley MS, Majam V, Mahajan B, Gerald N, Anantharaman V, Ward JM, Faucette LJ, McCutchan TF, Zheng H, Terabe M, Berzofsky JA, Aravind L, Kumar S.

PLoS One. 2009 Aug 27;4(8):e6793. doi: 10.1371/journal.pone.0006793.

4.

Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.

Maximova OA, Faucette LJ, Ward JM, Murphy BR, Pletnev AG.

J Histochem Cytochem. 2009 Oct;57(10):973-89. doi: 10.1369/jhc.2009.954180. Epub 2009 Jul 6.

5.

Large-scale performance and design for construction activity erosion control best management practices.

Faucette LB, Scholl B, Beighley RE, Governo J.

J Environ Qual. 2009 Apr 27;38(3):1248-54. doi: 10.2134/jeq2008.0415. Print 2009 May-Jun.

PMID:
19398523
6.

Storm water pollutant removal performance of compost filter socks.

Faucette LB, Cardoso-Gendreau FA, Codling E, Sadeghi AM, Pachepsky YA, Shelton DR.

J Environ Qual. 2009 Apr 27;38(3):1233-9. doi: 10.2134/jeq2008.0306. Print 2009 May-Jun.

PMID:
19398521
7.

Requirement for Sun1 in the expression of meiotic reproductive genes and piRNA.

Chi YH, Cheng LI, Myers T, Ward JM, Williams E, Su Q, Faucette L, Wang JY, Jeang KT.

Development. 2009 Mar;136(6):965-73. doi: 10.1242/dev.029868. Epub 2009 Feb 11.

8.

Host biomarkers and biological pathways that are associated with the expression of experimental cerebral malaria in mice.

Oakley MS, McCutchan TF, Anantharaman V, Ward JM, Faucette L, Erexson C, Mahajan B, Zheng H, Majam V, Aravind L, Kumar S.

Infect Immun. 2008 Oct;76(10):4518-29. doi: 10.1128/IAI.00525-08. Epub 2008 Jul 21.

9.

Novel ATP-competitive kinesin spindle protein inhibitors.

Parrish CA, Adams ND, Auger KR, Burgess JL, Carson JD, Chaudhari AM, Copeland RA, Diamond MA, Donatelli CA, Duffy KJ, Faucette LF, Finer JT, Huffman WF, Hugger ED, Jackson JR, Knight SD, Luo L, Moore ML, Newlander KA, Ridgers LH, Sakowicz R, Shaw AN, Sung CM, Sutton D, Wood KW, Zhang SY, Zimmerman MN, Dhanak D.

J Med Chem. 2007 Oct 4;50(20):4939-52. Epub 2007 Aug 29.

PMID:
17725339
10.

Naturally occurring murine norovirus infection in a large research institution.

Perdue KA, Green KY, Copeland M, Barron E, Mandel M, Faucette LJ, Williams EM, Sosnovtsev SV, Elkins WR, Ward JM.

J Am Assoc Lab Anim Sci. 2007 Jul;46(4):39-45.

PMID:
17645294
11.

Non-opsonising aggregates of IgG and complement in haemoglobin C erythrocytes.

Brittain NJ, Erexson C, Faucette L, Ward J, Fujioka H, Wellems TE, Fairhurst RM.

Br J Haematol. 2007 Feb;136(3):491-500. Epub 2006 Dec 8.

PMID:
17156402
12.

Pathology of immunodeficient mice with naturally occurring murine norovirus infection.

Ward JM, Wobus CE, Thackray LB, Erexson CR, Faucette LJ, Belliot G, Barron EL, Sosnovtsev SV, Green KY.

Toxicol Pathol. 2006;34(6):708-15.

PMID:
17074739
13.

Immunohistochemical markers for the rodent immune system.

Ward JM, Erexson CR, Faucette LJ, Foley JF, Dijkstra C, Cattoretti G.

Toxicol Pathol. 2006;34(5):616-30. Review.

PMID:
17067947
14.

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB.

Oncogene. 1999 Jul 15;18(28):4047-54.

15.

Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.

Freyer AJ, Patil AD, Killmer L, Troupe N, Mentzer M, Carte B, Faucette L, Johnson RK.

J Nat Prod. 1997 Oct;60(10):986-90.

PMID:
9358640
16.

Two new nitrogenous sesquiterpenes from the sponge Axinyssa aplysinoides.

Patil AD, Freyer AJ, Reichwein R, Bean MF, Faucette L, Johnson RK, Haltiwanger RC, Eggleston DS.

J Nat Prod. 1997 May;60(5):507-10.

PMID:
9170294
17.

The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth.

Eng WK, Faucette L, McLaughlin MM, Cafferkey R, Koltin Y, Morris RA, Young PR, Johnson RK, Livi GP.

Gene. 1994 Dec 30;151(1-2):61-71.

PMID:
7530227
18.

Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.

Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP.

Mol Cell Biol. 1993 Oct;13(10):6012-23.

19.

A screen for inhibitors of DNA recombination: identification of two new spirostanol glycosides from Chamaedorea linearis.

Patil AD, Baures PW, Eggleston DS, Faucette L, Hemling ME, Westley JW, Johnson RK.

J Nat Prod. 1993 Sep;56(9):1451-8.

PMID:
8254345
20.

The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.

Koser PL, Eng WK, Bossard MJ, McLaughlin MM, Cafferkey R, Sathe GM, Faucette L, Levy MA, Johnson RK, Bergsma DJ, Livi GP.

Gene. 1993 Jul 30;129(2):159-65.

PMID:
8325502
21.

Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein.

Koltin Y, Faucette L, Bergsma DJ, Levy MA, Cafferkey R, Koser PL, Johnson RK, Livi GP.

Mol Cell Biol. 1991 Mar;11(3):1718-23.

22.

In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.

Hoke GD, McCabe FL, Faucette LF, Bartus JO, Sung CM, Jensen BD, Heys JR, Rush GF, Alberts DW, Johnson RK, et al.

Mol Pharmacol. 1991 Jan;39(1):90-7.

PMID:
1898982
23.

Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, et al.

J Med Chem. 1991 Jan;34(1):98-107.

PMID:
1846923
24.

Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates.

Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, Faucette LF, Johnson RK, Mirabelli CK, Sadler PJ.

J Med Chem. 1990 May;33(5):1386-92.

PMID:
2329559
25.

Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues.

Kruse LI, Ladd DL, Harrsch PB, McCabe FL, Mong SM, Faucette L, Johnson R.

J Med Chem. 1989 Feb;32(2):409-17.

PMID:
2913301
26.

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Eng WK, Faucette L, Johnson RK, Sternglanz R.

Mol Pharmacol. 1988 Dec;34(6):755-60.

PMID:
2849043
27.

A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.

Mirabelli CK, Sung CM, McCabe FL, Faucette LF, Crooke ST, Johnson RK.

Cancer Res. 1988 Oct 1;48(19):5447-54.

28.

Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds.

Hurley LH, Reck T, Thurston DE, Langley DR, Holden KG, Hertzberg RP, Hoover JR, Gallagher G Jr, Faucette LF, Mong SM, et al.

Chem Res Toxicol. 1988 Sep-Oct;1(5):258-68.

PMID:
2979741
29.

Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes: comparison with copper and gold.

Berners-Price SJ, Johnson RK, Giovenella AJ, Faucette LF, Mirabelli CK, Sadler PJ.

J Inorg Biochem. 1988 Aug;33(4):285-95.

PMID:
3139831
30.

Biological characterization and oncogene expression in human colorectal carcinoma cell lines.

Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M, Anzano M, Rieman D, Hoffstein S, Li DJ, et al.

Int J Cancer. 1988 Feb 15;41(2):287-96.

PMID:
3338874
31.

Tumorigenicity of the cyc- variant of the S49 murine lymphoma deficient in the Gs-alpha subunit of adenylate cyclase.

Stadel JM, Johnson RK, Mirabelli CK, Powers DA, Sung CM, Faucette LF, McCabe FL, Crooke ST.

Cancer Res. 1988 Feb 1;48(3):641-4.

32.

Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.

Mirabelli CK, Hill DT, Faucette LF, McCabe FL, Girard GR, Bryan DB, Sutton BM, Bartus JO, Crooke ST, Johnson RK.

J Med Chem. 1987 Dec;30(12):2181-90.

PMID:
3681888
33.

In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.

Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST.

Cancer Res. 1986 Nov;46(11):5486-93.

34.

Modulation of the antitumor and biochemical properties of bis(diphenylphosphine)ethane with metals.

Snyder RM, Mirabelli CK, Johnson RK, Sung CM, Faucette LF, McCabe FL, Zimmerman JP, Whitman M, Hempel JC, Crooke ST.

Cancer Res. 1986 Oct;46(10):5054-60.

35.

Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes.

Mirabelli CK, Johnson RK, Hill DT, Faucette LF, Girard GR, Kuo GY, Sung CM, Crooke ST.

J Med Chem. 1986 Feb;29(2):218-23.

PMID:
3081721
36.

Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models.

Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K, Crooke ST.

Cancer Res. 1985 Jan;45(1):32-9.

37.

Influence of pyrazofurin on the toxicity and antitumor activity of fluorinated pyrimidines in vivo.

Johnson RK, Howard WS, Faucette LF, Wodinsky I, Clement JJ.

Adv Enzyme Regul. 1980;19:309-33. No abstract available.

PMID:
7337031

Supplemental Content

Loading ...
Support Center